You can find more detail on B12 treatment timelines and schedules
In proof-of-concept studies, NNMT inhibitors (NNMTis) have demonstrated promise as potential treatments for obesity and obesity-related metabolic comorbidities (e.g., T2D, fatty liver) 8,9,13
It is prescribed to patients with obesity (body mass index of 30 or more) and overweight (body mass index of 27 or more) with a weight-related condition like cardiovascular disease, high blood pressure, or type 2 diabetes
Beyond gastric applications, BPC-157 shows therapeutic potential for lesions throughout the gastrointestinal tract, including esophagus, duodenum, small intestine, colon, liver, and pancreas
Role of cystoscopy and hydrodistention in the diagnosis of interstitial cystitis/bladder pain syndrome
[4] Some individuals might experience mild diarrhea or gastrointestinal upset after parenteral B-vitamin administration